

Curriculum Vitae

Dr. Carl van Walraven MD FRCP(C) MSc

Business Address: Clinical Epidemiology Unit, Ottawa Health Research Institute
F660 – Ottawa Hospital, Civic Site
1053 Carling Avenue
Ottawa, Ontario
K1Y 4E9
(613) 761 - 4903
(613) 761 - 5351

E - mail: carlv @ ohri.ca

Date of Birth: April 10, 1967

Citizenship: Canadian

PROFESSIONAL APPOINTMENTS

1. Assistant Professor / Active Staff, Department of Medicine
Ottawa Hospital – Civic Campus, University of Ottawa
2. Clinician Scientist
Clinical Epidemiology Unit – Loeb Health Research Institute, Ottawa
3. Scientist
Institute for Clinical Evaluative Sciences, Toronto
4. Assistant Professor, Department of Epidemiology and Community Medicine
University of Ottawa
5. Acting Associate Director
Clinical Epidemiology Unit - Loeb Health Research Institute, Ottawa
6. Assistant Professor, Department of Communications, Faculty of Arts
University of Ottawa

EDUCATION and PREVIOUS PROFESSIONAL POSITIONS:

| | |
|--------------------|--|
| 1998 | Master of Science in Epidemiology University of Ottawa |
| 1997 - 1998 | Research Fellow Institute for Clinical Evaluative Sciences, Toronto |
| 1997 - 1998 | Locum Tenens, Department of Medicine Sunnybrook Health Science Centre |
| 1995 - 1997 | Clinical Scholar - Epidemiology, Clinical Associate Staff, Ottawa Civic Hospital |
| 1994 - 1995 | Clinical Fellow - General Internal Medicine University of Ottawa |
| 1991- 1994 | Internal Medicine Residency Program University of Ottawa |
| 1987 - 1991 | Doctor of Medicine University of Toronto |
| 1985 - 1987 | Molecular Biology University College University of Toronto |

CERTIFICATION and LINCENSURE:

| | |
|-------------|--|
| 1995 | Fellow of the Royal College Physicians and Surgeons of Canada Internal Medicine |
| 1991 | Licentiate of the Medical Council of Canada |

PEER-REVIEWED PROGRAM SUPPORT

| | |
|------|--|
| 2000 | “The Effect of Communication on Patient Care” Physician Services Incorporated \$10,000 (Principal Investigator) |
| 1999 | “The Hospital Patient Database – A High Quality Clinical Database of Hospitalized Patients” Canadian Foundation for Innovation \$200,000 (Principal Investigator) |
| 1999 | “The Hospital Patient Database – A High Quality Clinical Database of Hospitalized Patients” Ontario Innovation Trust \$200,000 (Principal Investigator) |
| 1999 | “Evaluation of a Leukoreduction Program” Medical Research Council of Canada – Industrial Partner Program \$ 1.3 million (Co-investigator) |
| 1999 | “Collaboration for Better Health Care Through Better Information Management” The Change Foundation \$50 000 (Principal Investigator) |
| 1999 | “Evaluation of a Hospital Discharge Database – It’s Effects upon Inter-Physician Communication and Hospital Discharge Abstract Completion” J.W. Bickell Foundation \$24 798 (Principal Investigator) |
| 1999 | “Mammography surveillance in women following treatment for breast cancer” Canadian Coordinating Office for Health Technology Assessment \$25 000 (Co-Investigator) |
| 1998 | “When are repeat laboratory tests unnecessary?” Ontario Association of Medical Laboratories \$18 000 (Principal Investigator) |

PERSONAL AWARDS / SALARY SUPPORT

| | |
|-----------|---|
| 2000-2005 | Ontario Ministry of Health Career Scientist Award \$59,000 / year |
| 1998-2000 | Arthur Bond Scholarship for Innovative Health Systems Research Physicians Services Incorporated Foundation Renewed June 2000 \$50,000 / year |
| 1997-1998 | R. Samuel McLaughlin Foundation Fellowship, University of Ottawa \$50,000 / year |
| 1995 | Michael Brown Outstanding Resident Award Department of Medicine, Ottawa Civic Hospital |
| 1995 | Certificate of Teaching Excellence for Senior Residents Faculty of Medicine, University of Ottawa |
| 1986 | NSERC (Natural Sciences and Engineering Research Council of Canada) |

Summer Research Training Grant

PUBLICATIONS:

1. **van Walraven C**, Bell CM. Risk of 30-day death or readmission after discharge from hospital varies with day of discharge. Accepted **CMAJ**, January 2002.
2. **van Walraven C**, Goel V. The effect of a hepatitis serology testing algorithm on laboratory utilization. Accepted **Journal of Evaluation in Clinical Practice**, January 2002.
3. **van Walraven C**, Seth R, Austin PC, Laupacis A. The effect of discharge summaries on readmission to hospital. **Journal of General Internal Medicine** 2002;
4. Knoll GA, Sahgal A, Nair RC, **van Walraven C**, Graham J, Burns KD. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. **American Journal of Medicine** 2002; 112: 110-4.
5. **van Walraven C**. Guidelines and practicing physicians – who's guiding who? [Editorial] **Clinical Chemistry** 2002; 48: 9-10.
6. Grunfeld E, Noorani H, McGahan L, Paszat L, Coyle D, **van Walraven C**, Joyce J, Sawka C. Surveillance mammography after treatment of primary breast cancer: A systematic review. Accepted **The Breast**, September 2001.
7. **van Walraven C**, Seth R, Laupacis A. Hospital discharge summaries infrequently get to post-hospitalization physicians. **Canadian Family Physician** 2002; 48: 737-742.
8. **van Walraven C**, Dent B. The Effect of Weight Loss in Obese Patients on Short-Term Health Resource Utilization. **Journal of Evaluation in Clinical Practice** 2002; 8: 37-46.
9. **van Walraven C**, Mamdani M, Wells PS, Williams JI. Serotonin-receptor blocking antidepressants and gastrointestinal bleeding in the elderly. **BMJ** 2001; 323: 655-658.
10. **van Walraven C**, Demers SV. Coding diagnoses and procedures using a high-quality clinical database instead of a medical record review. **Journal of Evaluation in Clinical Practice** 2001; 7: 289-298.
11. **van Walraven C**, Forster AJ. The effect of remuneration on physician practice patterns – a time series analysis would have been better (letter). **CMAJ** 2001; 164: 1835.
12. Austin PC, Goel V, **van Walraven C**. Introduction to multi-level regression modelling. **Canadian Journal of Public Health** 2001; 92: 150-154
13. **van Walraven C**, Forster A, Parish DC, Dane FC, Chandra D, Durham MD, Whaley C, Stiell I. Validation of a clinical decision aid to discontinue in-hospital cardiac arrest resuscitations. **JAMA** 2001; 285: 1602-1606.
14. **van Walraven C**, Austin PC, Naylor C.D. Vitamin B12 injections versus oral supplements. How much money could be saved by switching from injections to pills? **Canadian Family Physician** 2001; 47: 79-86
15. Forster A, Tugwell P, **van Walraven C**. An hypothesis paper on practice environment and the provision of health care: could hospital occupancy rates effect quality? **Journal of Quality in Clinical Practice** 2000; 20 (2): 69-74.
16. **van Walraven C**, Goel V, Austin P. Why are unrecommended investigations ordered at the Periodic Health Examination? **Journal of Evaluation in Clinical Practice** 2000; 6(2): 215-224.

17. Mamdani MM, Tu K, **van Walraven C**, Austin PC, Naylor CD. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. **CMAJ** 2000;162(10):1421-4
18. **van Walraven C**, Naylor CD. Vitamin B12 injections in the elderly (letter). **CMAJ** 2000;162:1275
19. Mamdani MM, **van Walraven C**, Bica A, Williams JI, Naylor CD. Is there an association between fibrate use and cholecystectomy? **American Journal of Medicine** 2000; 108: 418-21.
20. McAlister FA, Clark HD, **van Walraven C**, Straus S, Lawson FME, Moher D, Mulrow C. The medical review article revisited: Has the science improved? **Annals of Internal Medicine** 1999; 131: 947-951.
21. **van Walraven C**, Mahon JL, Moher D, Bohm C, Laupacis A. Surveying physicians to determine the minimal important difference: Implications for sample size calculation. **Journal of Clinical Epidemiology** 1999; 52: 717-723.
22. **van Walraven C**, Rokosh E. What is necessary for high-quality discharge summaries? **American Journal of Medical Quality** 1999; 14: 160-169
23. **van Walraven C**, Naylor CD. Use of vitamin B12 injections among elderly patients by primary care practitioners in Ontario. **CMAJ** 1999; 161: 146-9
24. Fergusson D, **van Walraven C**, Coyle D, Laupacis A, for The International Study of Peri-operative transfusion (ISPOT) Investigators. Economic evaluations of technologies to minimize perioperative transfusion: a systematic review of published studies. **Transfusion Medicine Reviews** 1999;13:106-17
25. **van Walraven C**, Laupacis A, Seth R, Wells G. A randomized controlled trial comparing dictated and database discharge summaries. **CMAJ** 1999; 160: 319-26
26. **van Walraven C**, Forster AJ, Stiell IG. Derivation of a clinical decision rule for the discontinuation of in-hospital cardiac resuscitation. **Archives of Internal Medicine** 1999;159:129-134
27. **van Walraven C**, Goel V, Chan B. The effect of population based interventions to change laboratory utilization: A time-series analysis. **JAMA** 1998; 280: 2028-2033.
28. **van Walraven C**, Stiell I, Wells G, Hebert PC, Vandemheem K. Do Advanced Cardiac Life Support drugs improve resuscitation from in-hospital cardiac arrest? **Annals of Emergency Medicine** 1998; 32: 554-553.
29. **van Walraven C**, Naylor CD. Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits. **JAMA** 1998; 280: 550-558
30. **van Walraven C**, Duke SM, Weinberg AL, Wells PS. Family physicians prefer standardized discharge summaries: a survey. **Canadian Family Physician** 1998; 44: 62-69
31. **van Walraven C**, Paterson MJ, Kapral M, et al. Appropriateness of primary hip and knee replacements in regions of Ontario with high versus low utilization rates. **CMAJ** 1996; 155: 697-706.
32. **van Walraven C**, Hebert PC. A reader's guide to the evaluation of prognostic studies. **Postgraduate Medical Journal** 1996; 72: 6 – 11
33. **van Walraven C**, Weinberg AL. Quality assessment of a discharge summary system. **CMAJ** 1995; 152: 1437 – 1442
34. **van Walraven C**, Wong B, Ugnat AM, Naylor CD. False-positive coding for acute myocardial infarction on hospital discharge records: Chart audit results from a tertiary care centre. **Canadian Journal Cardiology** 1990; 6(9): 383 – 8

MANUSCRIPTS UNDER REVIEW

1. **van Walraven C**, Hart RG, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, Laupacis A. A clinical prediction rule to identify patients with atrial fibrillation who have a low stroke risk while taking ASA. Submitted **Archives of Internal Medicine** March 2002.
2. Marshall SC, Spasoff R, Nair R, **van Walraven C**. A population-based study evaluating restricted driver licensing for medical impairments. Submitted **CMAJ** (2nd Review), April 2002.
3. **van Walraven C**, Mamdani M, Cohn A, Katib Y, Walker M, Rodger MA. A population-based cohort study to determine if preeclampsia increases the risk of subsequent thromboembolism. Submitted **BMJ** December 2001.
4. **van Walraven C**, Mamdani M, Fang J, Austin PC. Continuity of care and patient outcomes after discharge from hospital. Submitted **American Journal of Medicine** March 2002.
5. Clark HD, Code C, **van Walraven C**, Karovitch A, Keely E. Screening for type 2 diabetes mellitus in women with gestational diabetes: Did the 1998 Canadian Diabetes Association Guidelines change practice? Submitted **CMAJ** February 2002.
6. Forster A, Wells G, Lee A, **van Walraven C**. The effect of hospital occupancy on access to hospital for patients presenting to the emergency room. Submitted **Journal of Quality in Clinical Practice**, March 2002
7. Seth R, Magner P, Matzinger F, **van Walraven C**. How far is the sternal angle from the mid-right atrium? Submitted **Journal of General Internal Medicine** January 2002.
8. **van Walraven C**, Forster A. Survivor treatment selection bias (letter). Submitted **American Journal of Medicine** February 2002.

THESES SUPERVISED

- 2001 **Is there an association between hospital occupancy and quality of care?** Dr. Alan Forster, Master of Science in Epidemiology, University of Ottawa (Co-Supervisor)
- 1999 **Evaluation of restricted driver licensing for medical impairments in Saskatchewan.** Dr. Shawn Calder Marshall, Master of Science in Epidemiology, University of Ottawa (Co-Supervisor)

POSTERS AND PRESENTATIONS

1. What is significant? Factors causing variation in the minimal important difference and their implications for clinical trials.
12th Annual Meeting of the International Society of Technology Assessment in Health Care. San Francisco, California. June 26, 1996.
2. Association of drug therapy and resuscitation from cardiac arrest in hospital: Limited role of advanced cardiac life support drugs.
Annual meeting of the Society for Academic Emergency Medicine.
Washington D.C. May 20, 1997.
3. A randomized controlled trial comparing dictated and database discharge summaries.
14th Annual Meeting of the International Society of Technology Assessment in Health Care. Ottawa, Ontario. June 4, 1998.
4. The effect of population based interventions to change laboratory utilization: A time-series analysis.
14th Annual Meeting of the International Society of Technology Assessment in Health Care. Ottawa, Ontario. June 4, 1998.

INVITED TALKS

- | | |
|----------------|--|
| January 2000 | Using administrative databases to study laboratory utilization. Health Care Data: Research, Planning, and Decision – Making ICES and Central East Health Information Partnership Toronto ON |
| May 1999 | Utilization of laboratory tests at the periodic health examination MDS Metro Laboratory Services 22 nd Annual Spring Conference Burnaby B.C. |
| September 1998 | Laboratory utilization in Ontario 25 th Annual Convention, Ontario Society of Clinical Chemists Toronto ON |

SCHOLARLY and PROFESSIONAL ACTIVITIES:

| | |
|-----------------------------|---|
| Jan 2002 | Manuscript reviewer – Surgery |
| Nov 2001 | Manuscript reviewer – CMAJ |
| Nov 2001 | Member, Committee on Quality of Health Care in Canadian Hospitals, CIHR |
| Nov 2001 | Grant reviewer – Canadian Institutes for Health Research |
| Oct 2001 | Manuscript reviewer – The Lancet |
| Sept 2001 | Manuscript reviewer – Clinical Chemistry |
| Jun 2001 | Manuscript reviewer – Clinical Chemistry |
| Feb 2001 | Grant reviewer – Canadian Institutes for Health Research |
| Aug 2000 | Manuscript reviewer – CMAJ |
| Aug 2000 - | Steering committee for evaluation of ACES+ system |
| May 2000 | Manuscript reviewer – Medscape General Medicine |
| Jan 2000 | Grant reviewer – Medical Research Council of Canada |
| Jan 2000 | Manuscript reviewer – CMAJ |
| Jan 2000 | Manuscript reviewer – The American Journal of Managed Care |
| Dec 1999 | Grant reviewer – The Physicians' Services Incorporated Foundation |
| June 1999 | Manuscript reviewer – Journal of Clinical Epidemiology |
| March 1999 | Grant reviewer – The Physicians' Services Incorporated Foundation |
| January 1999 | Grant reviewer – Banting and Best Research in Diabetes Program |
| October 1998 | Member, National ICD – 10 Modification Advisory Task Force Canadian Institute for Health Information |
| Nov 1995 – Sept 1996 | Member - Evidence-Based Medicine Group University of Ottawa, Faculty of Medicine Lead co-author of Prognosis Module, and Instructor |
| May 1996 | Manuscript reviewer - European Journal of Epidemiology |
| October 1995 | Examiner MCCQE II Medical Council of Canada |
| Jan - July 1995 | Chief Medical Resident Ottawa Civic Hospital |
| Summer 1994 | Visiting Research Fellow Institute for Clinical Evaluative Sciences |